CLINICAL_TRIALS
trial_result
· 2017-07-18
Clinical Trial Update: A Study of Cabozantinib (XL184) vs Everolimus in Subjects With Metastatic Renal Cell Carcinoma [Phase 3]
Summary
Phase 3 trial comparing cabozantinib to everolimus in metastatic renal cell carcinoma has completed with results posted in 2017.
Upgrade for the full analysis, importance score, and drug timeline.
Diseases / indications
Drugs mentioned
Snippet
Sponsor: Exelixis | Conditions: Renal Cell Carcinoma | Phase 3 | Status: COMPLETED | Results posted: 2017-07-18